Somatostatin receptors in pituitary somatotroph adenomas as predictors of response to somatostatin receptor ligands: A pathologist's perspective.
SST2
immunoreactivity score
pituitary adenoma
somatostatin receptor ligands
somatostatin receptors
somatotropinomas
Journal
Brain pathology (Zurich, Switzerland)
ISSN: 1750-3639
Titre abrégé: Brain Pathol
Pays: Switzerland
ID NLM: 9216781
Informations de publication
Date de publication:
30 Oct 2024
30 Oct 2024
Historique:
received:
20
07
2024
accepted:
04
10
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
aheadofprint
Résumé
There are five subtypes of somatostatin receptors (SST1-5), which are expressed in several types of solid neoplasms, neuroendocrine tumors, and pituitary adenomas. Most commonly, SST2 and SST5, are of interest regarding diagnostic, treatment, and prognostic purposes. In this article the basic biological characteristics of SST are briefly reviewed, and focus given to the immunohistochemical evaluation of SST2 and SST5 in growth hormone (GH)-secreting pituitary tumors, and their quantification as predictors of response to treatment with somatostatin receptor ligands (SRL), the mainstay of the pharmacological therapy available for these tumors. Although many different scoring systems for SST2 immunohistochemistry showing correlation with SRL response have been reported, among which the immunoreactivity score (IRS) has been the most consistently used, a universally validated immunohistochemical technique and scoring scheme is lacking. Efforts should be made on collaborative multicenter studies aiming at validating homogeneous immunostaining protocols and a scoring system for SST2 and SST5 expression, to help clinicians to define the optimal therapeutic strategy for the patients with somatotroph tumors.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13313Informations de copyright
© 2024 The Author(s). Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology.
Références
Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol. 2013;34(3):228–252.
Reubi J, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype‐selective ligands. Eur J Nucl Med. 2001;28(7):836–846.
Czapiewski P, Kunc M, Gorczyński A, Haybaeck J, Okoń K, Reszec J, et al. Frequent expression of somatostatin receptor 2a in olfactory neuroblastomas: a new and distinctive feature. Hum Pathol. 2018;79:144–150.
Menke JR, Raleigh DR, Gown AM, Thomas S, Perry A, Tihan T. Somatostatin receptor 2a is a more sensitive diagnostic marker of meningioma than epithelial membrane antigen. Acta Neuropathol. 2015;130(3):441–443.
Lechner M, Schartinger VH, Steele CD, Nei WL, Ooft ML, Schreiber LM, et al. Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy. Nat Commun. 2021;12(1):117.
Qian ZR, Li T, Ter‐Minassian M, Yang J, Chan JA, Brais LK, et al. Association between somatostatin receptor expression and clinical outcomes in neuroendocrine tumors. Pancreas. 2016;45(10):1386–1393.
Xu Y, Quan Z, Zhan Y, Wang H, Luo J, Wang W, et al. SSTR2 positively associates with EGFR and predicts poor prognosis in nasopharyngeal carcinoma. J Clin Pathol. 2023:jcp‐2023‐208987:1–6.
Kim JY, Kim J, Kim YI, Yang DH, Yoo C, Park IJ, et al. Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors. Sci Rep. 2024;14(1):4047.
Appay R, Tabouret E, Touat M, Carpentier C, Colin C, Ducray F, et al. Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome. Acta Neuropathol Commun. 2018;6(1):89.
Eychenne R, Bouvry C, Bourgeois M, Loyer P, Benoist E, Lepareur N. Overview of radiolabeled somatostatin analogs for cancer imaging and therapy. Molecules. 2020;25:4012 https://www.mdpi.com/1420-3049/25/17/4012/htm
Mete O, Perry A, Lopes MBS, Yamada S, Ezzat S. Anterior pituitary neuroendocrine tumours (PitNETs): somatotroph PitNET/adenoma. In: WHO Classification of Tumours Editorial Board, editor. Endocrine and neuroendocrine tumours. Lyon (France): International Agency for Research on Cancer; 2022. (WHO classification of tumours series, 5th ed.; vol. 10). https://tumourclassification.iarc.who.int/chapters/53
Lamback EB, Wildemberg LE, Gadelha MR. Current opinion on the diagnosis and management of non‐functioning pituitary adenomas. Expert Rev Endocrinol Metab. 2021;16(6):309–320.
Capatina C, Hanzu FA, Hinojosa‐Amaya JM, Fleseriu M. Medical treatment of functional pituitary adenomas, trials and tribulations. J Neuro‐Oncol. 2024;168(2):197–213.
Kasuki L, Wildemberg LE, Gadelha MR. Management of endocrine disease: personalized medicine in the treatment of acromegaly. Eur J Endocrinol. 2018;178(3):R89–R100.
Gadelha MR, Wildemberg LE, Kasuki L. The future of somatostatin receptor ligands in acromegaly. J Clin Endocrinol Metab. 2022;107(2):297–308.
Gatto F, Feelders RA, van der Pas R, Kros JM, Waaijers M, Sprij‐Mooij D, et al. Immunoreactivity score using an anti‐sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2013;98(1):E66–E71.
Takei M, Suzuki M, Kajiya H, Ishii Y, Tahara S, Miyakoshi T, et al. Immunohistochemical detection of somatostatin receptor (SSTR) subtypes 2A and 5 in pituitary adenoma from acromegalic patients: good correlation with preoperative response to octreotide. Endocr Pathol. 2007;18(4):208–216.
Soukup J, Hornychova H, Manethova M, Michalova K, Michnova L, Popovska L, et al. Predictive and prognostic significance of tumour subtype, SSTR1‐5 and e‐cadherin expression in a well‐defined cohort of patients with acromegaly. J Cell Mol Med. 2021;25(5):2484–2492.
Fougner SL, Borota OC, Berg JP, Hald JK, Ramm‐Pettersen J, Bollerslev J. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clin Endocrinol. 2008;68(3):458–465.
Thodou E, Kontogeorgos G, Theodossiou D, Pateraki M. Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas. J Clin Pathol. 2006;59(3):274–279.
Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20(3):157–198.
Benali N, Ferjoux G, Puente E, Buscail L, Susini C. Somatostatin receptors. Digestion. 2000;62(Suppl 1):27–32.
Rosenbaum DM, Rasmussen SGF, Kobilka BK. The structure and function of G‐protein‐coupled receptors. Nature. 2009;459(7245):356–363.
Günther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, et al. International union of basic and clinical pharmacology. CV. Somatostatin receptors: structure, function, ligands, and new nomenclature. Pharmacol Rev. 2018;70(4):763–835.
Unger N, Ueberberg B, Schulz S, Saeger W, Mann K, Petersenn S. Differential expression of somatostatin receptor subtype 1–5 proteins in numerous human normal tissues. Experimental and Clinical Endocrinology & Diabetes. 2012;120(8):482–489.
Ben‐Shlomo A, Melmed S. Pituitary somatostatin receptor signaling. Trends Endocrinol Metab. 2010;21(3):123–133.
Patel YC, Greenwood M, Kent G, Panetta R, Srikant CB. Multiple gene transcripts of the somatostatin receptor SSTR2: tissue‐selective distribution and cAMP regulation. Biochem Biophys Res Commun. 1993;192(1):288–294.
Durán‐Prado M, Gahete MD, Martínez‐Fuentes AJ, Luque RM, Quintero A, Webb SM, et al. Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. J Clin Endocrinol Metab. 2009;94(7):2634–2643.
Corbetta S, Ballaré E, Mantovani G, Lania A, Losa M, Di Blasio AM, et al. Somatostatin receptor subtype 2 and 5 in human GH‐secreting pituitary adenomas: analysis of gene sequence and mRNA expression. Eur J Clin Investig. 2001;31(3):208–214.
Ballarè E, Persani L, Lania AG, Filopanti M, Giammona E, Corbetta S, et al. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab. 2001;86(8):3809–3814.
Marina D, Burman P, Klose M, Casar‐Borota O, Luque RM, Castaño JP, et al. Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues—observations in two patients with acromegaly and severe headache. Growth Hormon IGF Res. 2015;25(5):262–267.
Ben‐Shlomo A, Liu NA, Melmed S. Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas. Pituitary. 2017;20(1):93–99.
Patel YC, Greenwood MT, Warszynska A, Panetta R, Srikant CB. All five cloned human somatostatin receptors (hSSTR1‐5) are functionally coupled to adenylyl cyclase. Biochem Biophys Res Commun. 1994;198(2):605–612.
Koch BD, Schonbrunn A. The somatostatin receptor is directly coupled to adenylate cyclase in GH4Ci pituitary cell membranes*. Endocrinology. 1984;114(5):1784–1790.
Reisine T, Axelrod J. Prolonged somatostatin pretreatmentdesensitizes somatostatin's inhibition of receptor‐mediated release of adrenocorticotropin hormone and sensitizes adenylate cyclase. Endocrinology. 1983;113(2):811–813.
Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S, Morgan B, et al. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid‐stimulating hormone, and prolactin regulation. J Clin Invest. 1997;99(4):789–798.
Zatelli MC, Piccin D, Tagliati F, Ambrosio MR, Margutti A, Padovani R, et al. Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)‐ and prolactin (PRL)‐secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion. J Clin Endocrinol Metab. 2003;88(6):2797–2802.
Yang SK, Parkington HC, Blake AD, Keating DJ, Chen C. Somatostatin increases voltage‐gated K+ currents in GH3 cells through activation of multiple somatostatin receptors. Endocrinology. 2005;146(11):4975–4984.
Yamashita N, Shibuya N, Ogata E. Hyperpolarization of the membrane potential caused by somatostatin in dissociated human pituitary adenoma cells that secrete growth hormone. Proc Natl Acad Sci USA. 1986;83(16):6198–6202.
Florio T. Somatostatin/somatostatin receptor signalling: phosphotyrosine phosphatases. Mol Cell Endocrinol. 2008;286(1–2):40–48.
Cheung NW, Boyages SC. Somatostatin‐14 and its analog octreotide exert a cytostatic effect on GH3 rat pituitary tumor cell proliferation via a transient G0/G1 cell cycle block. Endocrinology. 1995;136(10):4174–4181.
Srikant CB. Cell cycle dependent induction of apoptosis by somatostatin analog SMS 201‐995 in AtT‐20 mouse pituitary cells. Biochem Biophys Res Commun. 1995;209(2):400–406.
Dent P, Reardon DB, Wood SL, Lindorfer MA, Graber SG, Garrison JC, et al. Inactivation of raf‐1 by a protein‐tyrosine phosphatase stimulated by GTP and reconstituted by Galphai/o subunits. J Biol Chem. 1996;271(6):3119–3123.
Wilkinson GF, Feniuk W, Humphrey PP. Characterization of human recombinant somatostatin sst5 receptors mediating activation of phosphoinositide metabolism. Br J Pharmacol. 1997;121(1):91–96.
Rhie DJ, Sung JH, Ha US, Kim HJ, Min DS, Hahn SJ, et al. Endogenous somatostatin receptors mobilize calcium from inositol 1,4,5‐trisphosphate‐sensitive stores in NG108‐15 cells. Brain Res. 2003;975(1–2):120–128.
Wilkinson GF, Feniuk W, Humphrey PP. Homologous and heterologous desensitisation of somatostatin‐induced increases in intracellular Ca2+ and inositol 1,4,5‐trisphosphate in CHO‐K1 cells expressing human recombinant somatostatin sst5 receptors. Eur J Pharmacol. 1997;340(2–3):277–285.
Cordelier P, Estève JP, Bousquet C, Delesque N, O'Carroll AM, Schally AV, et al. Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5. Proc Natl Acad Sci USA. 1997;94(17):9343–9348.
D'Arcy MS. Cell death: a review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int. 2019;43(6):582–592.
Hafezi S, Rahmani M. Targeting BCL‐2 in cancer: advances, challenges, and perspectives. Cancers (Basel). 2021;13(6):1292.
Fritsch M, Günther SD, Schwarzer R, Albert MC, Schorn F, Werthenbach JP, et al. Caspase‐8 is the molecular switch for apoptosis, necroptosis and pyroptosis. Nature. 2019;575(7784):683–687.
Thangaraju M, Sharma K, Leber B, Andrews DW, Shen SH, Srikant CB. Regulation of acidification and apoptosis by SHP‐1 and Bcl‐2. J Biol Chem. 1999;274(41):29549–29557.
Hofland LJ, Lamberts SWJ. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev. 2003;24(1):28–47.
Weich A, Rogoll D, Peschka M, Weich W, Pongracz J, Brand M, et al. Wnt/β‐catenin modulating drugs regulate somatostatin receptor expression and internalization of radiolabelled octreotide in neuroendocrine tumor cells. Nucl Med Commun. 2023;44(4):259–269.
Reubi JC, Kappeler A, Waser B, Laissue J, Hipkin RW, Schonbrunn A. Immunohistochemical localization of somatostatin receptors sst2A in human tumors. Am J Pathol. 1998;153(1):233–245.
Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WAP, Kooij PPM, Oei HY, et al. Somatostatin receptor scintigraphy with [111In‐DTPA‐d‐Phe1]‐ and [123I‐Tyr3]‐octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20(8):716–731.
Reubi JC, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res. 1994;54(13):3455–3459.
Papotti M, Bongiovanni M, Volante M, Allìa E, Landolfi S, Helboe L, et al. Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. Virchows Arch. 2002;440(5):461–475.
Wildemberg LEA, Vieira Neto L, Costa DF, Nasciutti LE, Takiya CM, Alves LM, et al. Validation of immunohistochemistry for somatostatin receptor subtype 2A in human somatotropinomas: comparison between quantitative real time RT‐PCR and immunohistochemistry. J Endocrinol Investig. 2012;35(6):580–584.
Casarini APM, Jallad RS, Pinto EM, Soares IC, Nonogaki S, Giannella‐Neto D, et al. Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide‐lar treatment. Pituitary. 2009;12(4):297–303.
Volante M, Brizzi MP, Faggiano A, Rosa SL, Rapa I, Ferrero A, et al. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol. 2007;20(11):1172–1182.
Wildemberg LEA, Neto LV, Costa DF, Nasciuti LE, Takiya CM, Alves LM, et al. Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. J Endocrinol Investig. 2013;36(1):38–43.
Chinezu L, Vasiljevic A, Jouanneau E, François P, Borda A, Trouillas J, et al. Expression of somatostatin receptors, SSTR2A and SSTR 5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies. Hum Pathol. 2014;45(1):71–77.
Muhammad A, Coopmans EC, Gatto F, Franck SE, Janssen JA, van der Lely AJ, et al. Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression. J Clin Endocrinol Metab. 2019;104(3):915–924.
Chinezu L, Vasiljevic A, Trouillas J, Lapoirie M, Jouanneau E, Raverot G. Silent somatotroph tumour revisited from a study of 80 patients with and 1 without acromegaly and a review of the literature 2. Eur J Endocrinol. 2016;176(2):195–201.
Wildemberg LE, Da Silva Camacho AH, Miranda RL, Elias PCL, De Castro Musolino NR, Nazato D, et al. Machine learning‐based prediction model for treatment of acromegaly with first‐generation somatostatin receptor ligands. J Clin Endocrinol Metab. 2021;106(7):2047–2056.
Campana C, Van Koetsveld PM, Feelders RA, De Herder WW, Iyer AM, Van Velthuysen MLF, et al. Digital quantification of somatostatin receptor subtype 2a immunostaining: a validation study. Eur J Endocrinol. 2022;187(3):399–411.
Casar‐Borota O, Heck A, Schulz S, Nesland JM, Ramm‐Pettersen J, Lekva T, et al. Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long‐term effects of octreotide. J Clin Endocrinol Metab. 2013;98(11):E1730–E1739.
Ilie MD, Tabarin A, Vasiljevic A, Bonneville JF, Moreau‐Grange L, Schillo F, et al. Predictive factors of somatostatin receptor ligand response in acromegaly—a prospective study. J Clin Endocrinol Metab. 2022;107(11):2982–2991.
Rass L, Rahvar AH, Matschke J, Saeger W, Renné T, Aberle J, et al. Differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy? Hormones. 2022;21(1):79–89.
Iacovazzo D, Carlsen E, Lugli F, Chiloiro S, Piacentini S, Bianchi A, et al. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first‐generation somatostatin analogues: an immunohistochemical study. Eur J Endocrinol. 2016;174(2):241–250.
Goldsmith JD, Troxell ML, Roy‐Chowdhuri S, Colasacco CF, Edgerton ME, Fitzgibbons PL, et al. Principles of analytic validation of immunohistochemical assays: guideline update. Arch Pathol Lab Med. 2024;148(6):e111–e153.
Giustina A, Uygur MM, Frara S, Barkan A, Biermasz NR, Chanson P, et al. Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers. Pituitary. 2023;26(5):583–596.
Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER‐ICA) in breast cancer tissue. Pathologe. 1987;8(3):138–140.
Kontogeorgos G, Markussis V, Thodou E, Kyrodimou E, Choreftaki T, Nomikos P, et al. Association of pathology markers with somatostatin analogue responsiveness in acromegaly. Int J Endocrinol. 2022;2022:1–7.
Reubi JC, Waser B, Liu Q, Laissue JA, Schonbrunn A. Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: membranous versus intracellular location. J Clin Endocrinol Metab. 2000;85:3882–3891. https://academic.oup.com/jcem/article/85/10/3882/2854976
Franck SE, Gatto F, van der Lely AJ, Janssen JA, Dallenga AH, Nagtegaal AP, et al. Somatostatin receptor expression in GH‐secreting pituitary adenomas treated with long‐acting somatostatin analogues in combination with pegvisomant. Neuroendocrinology. 2017;105(1):44–53.
Baxi V, Edwards R, Montalto M, Saha S. Digital pathology and artificial intelligence in translational medicine and clinical practice. Mod Pathol. 2022;35(1):23–32.
Wu S, Yue M, Zhang J, Li X, Li Z, Zhang H, et al. The role of artificial intelligence in accurate interpretation of HER2 immunohistochemical scores 0 and 1+ in breast cancer. Mod Pathol. 2023;36(3):100054.
Kasajima A, Papotti M, Ito W, Brizzi MP, La Salvia A, Rapa I, et al. High interlaboratory and interobserver agreement of somatostatin receptor immunohistochemical determination and correlation with response to somatostatin analogs. Hum Pathol. 2018;72:144–152.
Körner M, Waser B, Christ E, Beck J, Reubi JC. A critical evaluation of sst3 and sst5 immunohistochemistry in human pituitary adenomas. Neuroendocrinology. 2018;106(2):116–127.
Fuchs TL, Sioson L, Sheen A, Clarkson A, Gill AJ. Immunohistochemical expression of somatostatin receptors SSTR2A and SSTR5 in 299 pituitary adenomas. Pathology. 2018;50(4):472–474. http://www.pathologyjournal.rcpa.edu.au/article/S0031302517304890/fulltext
Mayr B, Buslei R, Theodoropoulou M, Stalla GK, Buchfelder M, Schöfl C. Molecular and functional properties of densely and sparsely granulated GH‐producing pituitary adenomas. Eur J Endocrinol. 2013;169(4):391–400.
Fookeerah P, Varikatt W, Shingde M, Dexter MAJ, McLean M. Somatostatin receptor expression and clinical outcome of multilineage pituitary tumours expressing PIT1 and SF1. Endocr Connect. 2023;12(11):e230328.
Gadelha MR, Kasuki L, Korbonits M. Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab. 2013;24(5):238–246.
Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, et al. Pasireotide versus octreotide in acromegaly: a head‐to‐head superiority study. J Clin Endocrinol Metab. 2014;99(3):791–799.
Colao A, Bronstein MD, Brue T, De Marinis L, Fleseriu M, Guitelman M, et al. Pasireotide for acromegaly: long‐term outcomes from an extension to the Phase III PAOLA study. Eur J Endocrinol. 2020;182(6):583.
Gadelha M, Marques NV, Fialho C, Scaf C, Lamback E, Antunes X, et al. Long‐term efficacy and safety of pasireotide in patients with acromegaly: 14 years of single‐center real‐world experience. J Clin Endocrinol Metab. 2023;108(12):e1571–e1579.
Amarù J, Barbieri F, Arvigo M, Solari A, Bajetto A, Nista F, et al. Octreotide and pasireotide combination treatment in somatotroph tumor cells: predominant role of SST2 in mediating ligand effects. Cancers (Basel). 2021;13(8):1816.
Gil J, Marques‐Pamies M, Sampedro M, Webb SM, Serra G, Salinas I, et al. Data mining analyses for precision medicine in acromegaly: a proof of concept. Sci Rep. 2022;12(1):8979.
Cuevas‐Ramos D, Carmichael JD, Cooper O, Bonert VS, Gertych A, Mamelak AN, et al. A structural and functional acromegaly classification. J Clin Endocrinol Metab. 2015;100(1):122–131.
Giustina A, Barkhoudarian G, Beckers A, Ben‐Shlomo A, Biermasz N, Biller B, et al. Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord. 2020;21(4):667–678. https://pubmed.ncbi.nlm.nih.gov/32914330/
Henriques DG, Miranda RL, Dezonne RS, Wildemberg LE, Camacho AH d S, Chimelli L, et al. miR‐383‐5p, miR‐181a‐5p, and miR‐181b‐5p as predictors of response to first‐generation somatostatin receptor ligands in acromegaly. Int J Mol Sci. 2023;24(3):2875.
Wildemberg LE, Henriques D, Elias PCL, Lima CH, Musolino NR, Camacho AH, et al. gsp mutation is not a molecular biomarker of long‐term response to first‐generation somatostatin receptor ligands in acromegaly. Cancers (Basel). 2021;13(19):4857.
Gatto F, Wildemberg LE, Ferone D, Gadelha MR. Routine evaluation of somatostatin receptor type 2 in patients with acromegaly: do we still need more evidence? J Clin Endocrinol Metab. 2022;107(12):e4382–e4383.
Gatto F, Arvigo M, Ferone D. Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies. J Endocrinol Investig. 2020;43(11):1543–1553.
Coelho MCA, Vasquez ML, Wildemberg LE, Vázquez‐Borrego MC, Bitana L, Camacho AHDS, et al. Molecular evidence and clinical importance of β‐arrestins expression in patients with acromegaly. J Cell Mol Med. 2018;22(4):2110–2116.